Artwork

Treść dostarczona przez Going Anti-Viral. Cała zawartość podcastów, w tym odcinki, grafika i opisy podcastów, jest przesyłana i udostępniana bezpośrednio przez Going Anti-Viral lub jego partnera na platformie podcastów. Jeśli uważasz, że ktoś wykorzystuje Twoje dzieło chronione prawem autorskim bez Twojej zgody, możesz postępować zgodnie z procedurą opisaną tutaj https://pl.player.fm/legal.
Player FM - aplikacja do podcastów
Przejdź do trybu offline z Player FM !

Episode 31 - Will we ever have a cure for Hepatitis B? - Dr Kenneth Sherman

31:25
 
Udostępnij
 

Manage episode 450958191 series 3516544
Treść dostarczona przez Going Anti-Viral. Cała zawartość podcastów, w tym odcinki, grafika i opisy podcastów, jest przesyłana i udostępniana bezpośrednio przez Going Anti-Viral lub jego partnera na platformie podcastów. Jeśli uważasz, że ktoś wykorzystuje Twoje dzieło chronione prawem autorskim bez Twojej zgody, możesz postępować zgodnie z procedurą opisaną tutaj https://pl.player.fm/legal.

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Kenneth Sherman of Massachusetts General Hospital and Harvard Medical School about the possibility of a cure for hepatitis B. The World Health Organization estimates that 254 million people were living with chronic hepatitis B globally in 2022. Dr Saag and Dr Sherman discuss the lifecycle of hepatitis B including the role that covalently closed circular DNA (cccDNA) plays in the hepatitis B virus (HBV) replication cycle. Dr Sherman defines functional cure and provides an overview of the most promising cure strategies. They also discuss whether antiretroviral drugs like tenofovir, used in the treatment of HIV, can contribute toward a functional cure of hepatitis B. Dr Sherman discusses other strategies like capsid assembly modulators (CAMs), monoclonal antibodies, and toll-like receptor (TLR) agonists. Finally, they discuss the effectiveness of the hepatitis B vaccine in prevention and look forward to the future by considering a timeline for a cure based on the status of ongoing clinical trials.

0:00 – Introduction

1:23 – Overview of the lifecycle of hepatitis B

5:29 – Discussion of the most promising cure strategies

7:11 – Defining functional cure

10:56 – The role of drugs like tenofovir in a functional cure

13:39 – Targets that can affect viral production

16:04 – Potential of capsid assembly modulators (CAMs)

18:03 – Other strategies like immune modulators and monoclonal antibodies

22:29 – Interest in toll-like receptor (TLR) agonists and therapeutic vaccines

24:32 – Outlook for the future and the effectiveness of a hepatitis B vaccine in prevention

__________________________________________________
Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.

Going anti-Viral’s host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.
Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.
Follow Going anti-Viral on:
Apple Podcasts
YouTube
X
Facebook
Instagram
...

  continue reading

36 odcinków

Artwork
iconUdostępnij
 
Manage episode 450958191 series 3516544
Treść dostarczona przez Going Anti-Viral. Cała zawartość podcastów, w tym odcinki, grafika i opisy podcastów, jest przesyłana i udostępniana bezpośrednio przez Going Anti-Viral lub jego partnera na platformie podcastów. Jeśli uważasz, że ktoś wykorzystuje Twoje dzieło chronione prawem autorskim bez Twojej zgody, możesz postępować zgodnie z procedurą opisaną tutaj https://pl.player.fm/legal.

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Kenneth Sherman of Massachusetts General Hospital and Harvard Medical School about the possibility of a cure for hepatitis B. The World Health Organization estimates that 254 million people were living with chronic hepatitis B globally in 2022. Dr Saag and Dr Sherman discuss the lifecycle of hepatitis B including the role that covalently closed circular DNA (cccDNA) plays in the hepatitis B virus (HBV) replication cycle. Dr Sherman defines functional cure and provides an overview of the most promising cure strategies. They also discuss whether antiretroviral drugs like tenofovir, used in the treatment of HIV, can contribute toward a functional cure of hepatitis B. Dr Sherman discusses other strategies like capsid assembly modulators (CAMs), monoclonal antibodies, and toll-like receptor (TLR) agonists. Finally, they discuss the effectiveness of the hepatitis B vaccine in prevention and look forward to the future by considering a timeline for a cure based on the status of ongoing clinical trials.

0:00 – Introduction

1:23 – Overview of the lifecycle of hepatitis B

5:29 – Discussion of the most promising cure strategies

7:11 – Defining functional cure

10:56 – The role of drugs like tenofovir in a functional cure

13:39 – Targets that can affect viral production

16:04 – Potential of capsid assembly modulators (CAMs)

18:03 – Other strategies like immune modulators and monoclonal antibodies

22:29 – Interest in toll-like receptor (TLR) agonists and therapeutic vaccines

24:32 – Outlook for the future and the effectiveness of a hepatitis B vaccine in prevention

__________________________________________________
Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.

Going anti-Viral’s host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.
Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.
Follow Going anti-Viral on:
Apple Podcasts
YouTube
X
Facebook
Instagram
...

  continue reading

36 odcinków

Wszystkie odcinki

×
 
Loading …

Zapraszamy w Player FM

Odtwarzacz FM skanuje sieć w poszukiwaniu wysokiej jakości podcastów, abyś mógł się nią cieszyć już teraz. To najlepsza aplikacja do podcastów, działająca na Androidzie, iPhonie i Internecie. Zarejestruj się, aby zsynchronizować subskrypcje na różnych urządzeniach.

 

Skrócona instrukcja obsługi

Posłuchaj tego programu podczas zwiedzania
Odtwarzanie